

Contents

1	Epidemiology/Prevalence of Dyslipidemia in the General Population and in Patients with Chronic Kidney Disease.....	1
	Tevfik Ecdar	
2	Lipid Nephrotoxicity: New Concept for an Old Disease	9
	Xiong Zhong Ruan, Zac Varghese, and John Moorhead	
3	Hyperlipidemia as a Risk Factor for Progression of CKD in Nondiabetics.....	27
	Agata Kujawa-Szewieczek, Grzegorz Piecha, and Andrzej Więcek	
4	How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly.....	45
	Faruk Turgut, Ihsan Ustun, and Cumali Gokce	
5	CVD in CKD: Focus on the Dyslipidemia Problem.....	67
	Theodoros Kassimatis and David Goldsmith	
6	The CKD Patient with Dyslipidemia.....	93
	Valentina Batini and Stefano Bianchi	
7	Review of Clinical Trials Pertaining to Dyslipidemias in CKD.....	111
	Markus P. Schneider and Kai-Uwe Eckardt	
8	Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease	129
	Ali Olyaei, Jessica Lassiter, and Edgar V. Lerma	
9	Non-statin Therapies for CKD with Dyslipidemia.....	153
	Istvan Mucsi	
10	Dyslipidemia in Dialysis	179
	Yalcin Solak and Halil Zeki Tonbul	

11	Dyslipidemia in the Kidney Transplant Patient	203
	Rajan Kantilal Patel and Alan G. Jardine	
12	Dyslipidemia in Nephrotic Syndrome	213
	Minso Kim and Howard Trachtman	
13	Dyslipidemias in the Pediatric Chronic Kidney Disease Patient	231
	Zeynep Birsin Özçakar and Fatoş Yalçınkaya	
14	Dyslipidemias in the Geriatric Chronic Kidney Disease Patients	255
	Zeynel Abidin Ozturk and Zekeriya Ulger	
15	Apheresis Methods in Hyperlipidemias	269
	Serdar Sivgin	
16	Review of Current Guidelines: National Cholesterol Education Program and Kidney Disease Outcomes Quality Initiative as They Apply to CKD with Dyslipidemias	287
	Baris Afsar	
	Index	301